myTomorrows and CureLGMD2i Foundation Collaborate to Facilitate Clinical Trial Access for Limb Girdle Muscular Dystrophy 2I/R9 Patients

AMSTERDAM, Sept. 4, 2024 -- myTomorrows, a global health technology company dedicated to connecting patients with potential treatment options, has announced a new collaboration with the CureLGMD2i Foundation. This non-profit organization aims to raise awareness, provide advocacy, and secure funding for research and support for individuals suffering from Limb Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). The partnership will allow CureLGMD2i to utilize myTomorrows' comprehensive search engine of ongoing clinical trials, providing patients, caregivers, and healthcare professionals with current and easily accessible information about pre-approval treatments that may be pertinent to them, along with support during their engagement with these treatments.

LGMD2I/R9 is a rare variant of Muscular Dystrophy, a group of progressively debilitating diseases leading to significant muscle wasting and weakness. This form specifically impacts the shoulder, thigh, and hip muscles, placing patients at higher risks for cardiovascular, respiratory, and general mobility issues. Given the absence of a cure for LGMD2I/R9, it is crucial for patients to be well-informed about all available treatment options, particularly clinical trials, which are often difficult to locate, comprehend, and navigate.

The new collaboration aims to increase awareness of potential treatment options among LGMD2I/R9 patients, their families, and healthcare providers, while simplifying the process of identifying and understanding current clinical trial options. Patients and physicians will have the ability to easily access myTomorrows' global clinical trials search engine to find relevant LGMD2I/R9 pre-approval treatment options. Additionally, myTomorrows' expert patient navigators will assist in clarifying the complex terminology surrounding clinical trials and provide support to patients and their loved ones throughout the process, enabling them to make well-informed treatment decisions.

"We are excited about partnering with CureLGMD2i to help increase awareness of clinical trials among LGMD2I/R9 patients, their families, and the healthcare providers who treat them," stated Dr. Michel van Harten, CEO of myTomorrows. "This collaboration enhances our commitment to empowering patients and healthcare professionals with the knowledge and confidence they need throughout their treatment journeys. As the biopharmaceutical industry continues to develop new treatments for this genetic disease, we will ensure that those affected have access to the most current information necessary to make the best decisions for their needs."

"Our vision is a future where individuals dealing with this rare disease receive early treatment and live without the associated challenges," said Kelly Brazzo, CEO and co-founder of CureLGMD2i. "We are eager to further this mission with the help of myTomorrows, providing our community of patients and their families the support they need to access and utilize pre-approval treatment options."

Patients, their caregivers, and physicians can explore more about available clinical trials for Limb Girdle Muscular Dystrophy Type 2I/R9 through myTomorrows' platform.

myTomorrows is a global health technology firm focused on breaking down barriers for patients seeking treatment options. Utilizing advanced technology, the company has built a powerful search engine that efficiently connects patients, physicians, trial sites, and biopharmaceutical companies, ensuring straightforward and transparent access to drugs in development. Headquartered in Amsterdam with an office in New York City, myTomorrows has assisted over 11,000 patients and 2,000 physicians across more than 40 countries.

The CureLGMD2i Foundation was established by the Brazzo Family following their daughter Samantha's diagnosis with Limb Girdle Muscular Dystrophy Type 2I/R9 at the age of two. At the time, there were no FDA-approved therapies for LGMD2I/R9. The foundation, originally known as The Samantha J. Brazzo Foundation, was created to raise awareness, advocate for the patient community, and fund research to support individuals suffering from LGMD2I/R9.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!